

SUPPLY CHAIN DISRUPTIONS IN ESSENTIAL MEDICAL PRODUCTS

Dr. Esha Saha

Assistant Professor

Department of Management Studies and Industrial Engineering
Indian Institute of Technology (Indian School of Mines) Dhanbad
Dhanbad, Jharkhand, India

Abstract

Essential medical products, including medicines, vaccines, diagnostics, personal protective equipment, oxygen systems, medical devices and consumables, are indispensable to safe and continuous health care. Their availability depends on supply chains that coordinate forecasting, procurement, manufacturing, quality assurance, storage, transport, customs clearance, distribution and last-mile delivery. When any of these functions is disrupted, health facilities may experience stockouts, treatment delays, rationing and avoidable clinical risk. The COVID-19 pandemic made these vulnerabilities highly visible, but supply disruption is also produced by natural disasters, political instability, quality failures, export restrictions, market concentration, demand volatility, transport interruptions and weak information systems.

This study examines supply chain disruptions in essential medical products through a qualitative review of supply chain resilience literature, public-health guidance, pharmaceutical shortage reports and health-systems research. The analysis focuses on the main sources of disruption, the pathways through which disruptions affect availability, and the organisational controls that reduce vulnerability. Particular attention is given to demand shocks, dependence on single sources, production and regulatory bottlenecks, logistics constraints, allocation decisions, data visibility and inequitable access across regions and population groups.

The findings indicate that product availability is not determined by inventory alone. Resilient medical supply systems require coordinated demand planning, diversified and quality-assured suppliers, strategic buffer stocks, reliable cold-chain and transport capacity, interoperable information systems, transparent allocation rules and clear accountability across public and private actors. High-risk products need differentiated management because an interruption in a low-volume but life-saving medicine can be as harmful as a shortage of a high-volume commodity. Supply chain policies must therefore be clinically informed, equity-sensitive and designed for rapid adaptation.

The paper proposes a resilience framework that connects preparedness, visibility, sourcing, logistics, quality assurance, allocation and governance. It supports health authorities, procurement agencies, manufacturers, distributors and health facilities in reducing avoidable shortages and protecting continuity of essential care.

Keywords: Medical Supply Chains, Essential Medicines, Health Product Shortages, Supply Chain Resilience, Pharmaceutical Procurement, Logistics, Health Systems, Inventory Management, Emergency Preparedness, Equity in Access

1. INTRODUCTION

Essential medical products are the practical foundation of health-service delivery. A trained clinician cannot provide safe care when antibiotics, anaesthetics, diagnostic reagents, sterile consumables, oxygen supplies or protective equipment are unavailable. The consequences of shortage are not limited to procurement inconvenience. They may include postponed procedures, substitution with less suitable therapies, increased infection risk, higher treatment costs, reduced public

confidence and, in severe cases, preventable morbidity and mortality. For this reason, the management of medical product supply chains must be treated as a core health-system function rather than a back-office activity.

Medical supply chains are complex because they combine commercial markets with public-health obligations. Products often have strict quality requirements, limited shelf lives, storage conditions, batch traceability needs and specialised transport or cold-chain requirements. Many products also depend on

global networks for active pharmaceutical ingredients, components, packaging materials, manufacturing equipment and shipping capacity. A disruption at one point can propagate through the network and reach hospitals, pharmacies and community services far from the original source. Supply-chain risk is therefore systemic: it emerges from interdependence as well as from individual operational failures.

The pandemic period showed how a sudden rise in demand can expose weaknesses in forecasting, procurement contracts, production capacity and international logistics. Governments and hospitals competed for the same masks, ventilators, diagnostic supplies, oxygen equipment and medicines. Export controls, border delays and limited freight capacity intensified shortages, while inaccurate or delayed data made it difficult to direct scarce products to the facilities with the greatest clinical need. Similar patterns can arise during local outbreaks, floods, conflict, cyber incidents, industrial accidents and disruptions affecting energy or transport infrastructure.

A resilient response requires more than purchasing larger quantities after a crisis begins. It involves anticipating critical products, mapping dependencies, identifying alternative suppliers, validating quality requirements, maintaining appropriate stock policies, improving end-to-end visibility and preparing fair allocation rules. The task is particularly important for products with few manufacturers, long production lead times, specialised inputs or regulatory restrictions. In such cases, market demand and price signals alone may not protect public access.

This paper investigates the causes, consequences and management of supply chain disruptions in essential medical products. It synthesises key literature and public-health principles, identifies critical points of vulnerability and develops a practical framework for improving continuity of supply. The purpose is to show that resilient medical supply chains are essential to patient safety,

Table 1: Summary of Key Literature on Supply Chain Disruptions in Essential Medical Products

public-health preparedness and equitable access to care.

2. LITERATURE REVIEW

The supply chain resilience literature explains that disruption management depends on the ability to anticipate shocks, absorb their immediate effects, adapt operations and recover without unacceptable loss of performance. Early work by Christopher and Peck and by Sheffi and Rice emphasised the value of visibility, collaboration, flexibility and redundancy. Later scholarship broadened the concept to include viability, learning, network design and the capacity to operate under changing conditions. These ideas are highly relevant to medical products because health systems cannot simply defer demand when a life-saving product is unavailable.

Health-product supply chains in low- and middle-income settings have long faced challenges related to fragmented procurement, weak storage capacity, limited workforce capability, unreliable transport, financing delays and incomplete consumption data. Yadav argues that underperformance is often rooted in system design and governance rather than in a single logistics activity. Essential medicine research similarly demonstrates that affordability and availability are interconnected: shortages can force providers and patients to rely on more expensive, less suitable or unregulated alternatives, with consequences for quality and equity.

The COVID-19 experience generated a large body of work on epidemic-related disruption. Studies highlight demand surges, supplier concentration, port and air-freight constraints, shortages of active ingredients and global competition for limited production capacity. They also show that emergency measures are more effective when built on pre-existing capabilities such as accurate inventory records, qualified supplier networks, clear regulatory procedures, trusted data sharing and coordinated distribution. The literature therefore supports a shift from reactive purchasing to resilient and risk-based supply governance.

S. No.	Author(s)	Year	Methodology	Key Focus	Major Findings
1	Christopher & Peck	2004	Conceptual study	Supply chain resilience	Visibility, collaboration and flexibility help organisations prepare for and recover from disruptions.
2	Sheffi & Rice	2005	Case-based analysis	Resilient enterprise	Recovery capacity depends on preparedness, response discipline and coordinated decision-making.
3	Tang	2006	Literature review	Supply chain risk management	Mitigation requires matching risk sources with suitable operational strategies.
4	Pettit et al.	2010	Conceptual framework	Resilience capabilities	Balance between vulnerabilities and capabilities is central to resilient supply systems.
5	Yadav	2015	Health-systems review	Health product supply chains	System design, governance and information gaps drive persistent underperformance.
6	Wirtz et al.	2017	Global policy review	Essential medicines	Universal access requires sustained availability, affordability and quality assurance.
7	FDA	2019	Policy report	Drug shortages	Manufacturing quality, market incentives and limited redundancy contribute to shortages.
8	Ivanov	2020	Simulation-based analysis	Epidemic disruption	Outbreaks can rapidly propagate through interconnected global supply networks.
9	Ivanov & Dolgui	2020	Position paper	Supply network viability	Survivability requires adaptive capacity rather than reliance on static efficiency alone.
10	Queiroz et al.	2020	Systematic review	Epidemic supply chains	Digital tools, collaboration and risk management became central research priorities.
11	Govindan et al.	2020	Decision support study	Health-care demand management	Demand prioritisation and allocation rules support response during epidemic surges.
12	Chowdhury et al.	2021	Systematic review	COVID-19 supply chain studies	Resilience, digitalisation, preparedness and humanitarian coordination are recurring themes.

3. OBJECT OF STUDY

The object of this study is the disruption of supply chains for essential medical products. The analysis examines the movement of products from demand estimation and supplier selection to manufacturing, quality assurance, procurement, storage, transport, distribution and use at the point of care. It focuses on the conditions that interrupt product availability and the safeguards that help maintain

continuity when normal supply arrangements fail.

The study covers essential medicines, vaccines, diagnostic reagents, personal protective equipment, oxygen-related products, medical devices, sterile consumables and other health commodities required for prevention, diagnosis, treatment and emergency response. These product groups differ in value, volume, temperature

sensitivity, regulatory status and lead time, but each may become critical when unavailable. The analysis therefore considers both routine supply performance and crisis conditions.

The central concern is whether supply systems can provide the right product, in the right quantity and quality, at the right location and time, while protecting equity and clinical priority. The study does not treat disruption as a purely commercial problem. It examines the effects of supply failure on patient care, public health, workforce safety and trust in health institutions.

KEY POINTS OF OBJECT OF STUDY

- To identify major causes of disruption in essential medical product supply chains.
- To examine demand volatility, supplier concentration, production constraints and logistics bottlenecks.
- To assess the role of forecasting, inventory policies and end-to-end visibility in preventing shortages.

- To analyse quality assurance, regulatory and traceability requirements during emergency sourcing.
- To evaluate the impact of export restrictions, customs delays and transport disruptions on access.
- To study allocation decisions and their implications for fairness across facilities and populations.
- To examine vulnerabilities associated with cold-chain products, short shelf life and specialised storage.
- To assess the use of digital systems for stock monitoring, early warning and supplier coordination.
- To identify governance responsibilities of manufacturers, procurement agencies, distributors and health facilities.
- To develop a practical resilience framework for essential medical product availability.

Table 2: Object of Study Framework

S. No.	Study Component	Description	Purpose
1	Demand planning	Forecasting of routine and surge requirements using consumption, morbidity and service data.	Reduce demand shocks and improve procurement timing.
2	Sourcing and procurement	Supplier selection, contract design, qualification and diversification.	Limit dependence on a single supplier or country.
3	Manufacturing and quality	Production capacity, active ingredients, quality systems and regulatory approvals.	Prevent supply interruption caused by production or compliance failures.
4	Inventory and storage	Safety stock, expiry management, warehouse capacity and cold-chain controls.	Maintain clinically appropriate buffers and reduce wastage.
5	Transport and distribution	Freight capacity, customs processes, route planning and last-mile delivery.	Ensure timely movement to facilities and communities.
6	Data visibility	Stock reporting, shipment tracking, consumption monitoring and alert systems.	Support rapid detection and response to emerging shortages.
7	Allocation and equity	Priority-setting for scarce products across locations and population groups.	Protect fairness, clinical need and continuity of essential services.
8	Governance and accountability	Roles, escalation pathways, audits and emergency decision protocols.	Create coordinated action across the supply chain.

4. RESEARCH METHODOLOGY

The study adopts a qualitative, document-based research design. It combines a thematic review of supply chain resilience scholarship, health-systems research, regulatory reports, medicine shortage guidance and public-health preparedness literature. This approach is appropriate because the study investigates the mechanisms, governance arrangements and practical controls that shape availability of essential medical products across diverse settings. Rather than presenting a single facility dataset, the paper synthesises evidence and concepts that can guide decision-making across procurement, logistics and health-service delivery.

4.1 RESEARCH DESIGN

- Study Type: Qualitative and document-based analysis
- Approach: Thematic review supported by comparative analysis of disruption risks and resilience controls
- Unit of Analysis: Essential medical product supply chains, including medicines, vaccines, diagnostics, devices and consumables
- Source Categories: Peer-reviewed literature, regulatory reports, public-health guidance, supply-chain frameworks and shortage analyses
- Core Dimensions: Preparedness, visibility, sourcing, manufacturing, quality, logistics, allocation, equity and governance
- Analytical Goal: Develop a practical framework for continuity of supply and rapid response to disruption

4.2 METHODOLOGICAL STEPS

- Step 1: Define essential medical product categories and map the major stages of their supply chains.
- Step 2: Review literature on supply chain resilience, risk management and health-product availability.
- Step 3: Identify disruption drivers, including demand spikes, production failures, supplier concentration, transport constraints and information gaps.
- Step 4: Develop an analysis matrix covering prevention, detection, response, recovery and long-term adaptation.
- Step 5: Compare routine supply vulnerabilities with emergency conditions

such as outbreaks, natural disasters and border restrictions.

- Step 6: Examine the relationship between operational disruption and patient-safety, equity and service-continuity outcomes.
- Step 7: Identify control measures involving forecasting, diversified sourcing, buffer stock, visibility systems, quality assurance and allocation rules.
- Step 8: Formulate a resilience framework that can be used by health authorities and supply-chain partners.

5. DATA ANALYSIS

The data analysis uses thematic comparison to examine how disruptions arise, how they propagate through the medical supply chain and what controls reduce their impact. The analysis treats availability as an outcome of interacting decisions rather than a simple stock-level measure. A product may appear available at a national warehouse while remaining inaccessible to a remote facility because of distribution delays, cold-chain limits, incomplete order data, payment constraints or unsuitable allocation. The following themes therefore consider both physical flow and decision quality.

5.1 DEMAND VOLATILITY AND FORECASTING GAPS

Demand for essential medical products can change rapidly when disease incidence rises, treatment protocols are revised, clinical services expand or public behaviour shifts. During outbreaks, demand may increase simultaneously across multiple regions, making it difficult for manufacturers and distributors to rebalance supply. Conventional forecasts that rely only on historical consumption can underestimate surge requirements, particularly when previous stockouts have suppressed recorded use. Health systems need forecasting approaches that combine consumption data with epidemiological indicators, planned service volumes, seasonality, population needs and emergency scenarios.

Weak demand visibility also creates the risk of over-ordering by individual facilities. When buyers fear shortages, they may place orders above actual requirements, further distorting market signals and leaving less stock for other locations. Coordinated order management, transparent allocation and regular

communication can reduce panic purchasing. In practice, forecasting should be linked to stock status, open orders, supplier lead times, shelf life and the clinical criticality of each product. The objective is not perfect prediction; it is early recognition of uncertainty and rapid adjustment before shortages become severe.

5.2 SUPPLIER CONCENTRATION AND MANUFACTURING CONSTRAINTS

Many essential products depend on a small number of manufacturers or on specialised inputs that are produced in limited locations. This concentration can lower unit costs during normal periods, but it increases exposure when a plant fails inspection, an active ingredient is delayed, a supplier experiences a cyber incident or an exporting country imposes restrictions. In pharmaceutical supply chains, quality-related production stoppages can be particularly difficult to address because alternative facilities require regulatory approval and may have limited spare capacity. Resilience requires an informed balance between efficiency and redundancy. Diversifying suppliers does not mean purchasing from unqualified sources during a crisis. It means pre-qualifying alternatives, maintaining technical specifications, understanding dependency on common inputs, designing contracts that support surge capacity and monitoring supplier financial and operational risks. For critical products, buyers should assess not only the direct supplier but also upstream dependencies such as active

ingredients, packaging, cold-chain materials, electronics and sterile components.

5.3 LOGISTICS, DISTRIBUTION AND LAST-MILE DELIVERY

Transport interruption can convert an adequate national supply position into local scarcity. Border delays, reduced flight schedules, fuel shortages, damaged roads, warehouse closures, labour constraints and shortages of refrigerated vehicles can delay products that are urgently needed or temperature-sensitive. Medical supply chains require contingency transport plans, route alternatives, priority customs procedures, validated packaging, temperature monitoring and reliable communication with receiving facilities. Last-mile delivery is especially important for rural, conflict-affected and disaster-affected areas where routine distribution routes may be weak.

The analysis also indicates that distribution performance must be assessed at facility level. Central inventory figures can conceal stockouts in peripheral clinics, while delayed consumption reporting can prevent reallocation of products before they expire. Regular stock reporting, proof-of-delivery records, cold-chain monitoring and exception alerts support a more accurate picture of availability. However, digital systems are useful only when staff can enter reliable data and when information is linked to clear response authority.

Table 3: Essential Medical Product Supply Chain Resilience Evaluation Matrix

Resilience Dimension	Primary Risk	Responsible Practice	Evidence / Control
Preparedness	No mapping of critical products or dependency risks	Classify essential products by clinical criticality, lead time and supply risk	Critical product list; risk register; scenario plans
Demand visibility	Late or unreliable consumption and stock data	Use routine reporting, stock status dashboards and surge indicators	Facility reports; stock dashboards; order monitoring
Sourcing	Dependence on one supplier, country or upstream input	Pre-qualify alternatives and use risk-informed contract design	Supplier map; qualification files; contract clauses
Manufacturing and quality	Production failure or quality-related release delay	Monitor supplier quality, capacity and regulatory status	Quality audits; batch-release data; shortage notifications
Inventory and storage	Inadequate buffer stock, expiry or poor	Set differentiated safety stocks and	Min-max levels; FEFO records; temperature

	temperature control	manage shelf life actively	logs
Logistics	Freight, customs or last-mile delivery disruption	Use contingency routes, priority clearance and delivery tracking	Transport plans; customs protocols; proof of delivery
Allocation and equity	Scarce products distributed without clinical prioritisation	Apply transparent allocation rules based on need and service continuity	Allocation policy; facility priority criteria; exception records
Governance	Unclear authority and fragmented crisis response	Define roles, escalation points and joint emergency coordination	Incident log; task-force minutes; after-action reviews

5.4 ALLOCATION, EQUITY AND CLINICAL PRIORITISATION

When supply cannot meet total demand, allocation becomes a clinical and ethical decision as well as a logistical one. A purely first-come, first-served approach can favour larger or better-connected institutions while leaving primary-care facilities and underserved communities without essential treatment. Conversely, equal distribution may ignore different disease burdens, service volumes and the need to preserve emergency capacity. Transparent allocation principles should be established before a crisis, communicated to stakeholders and updated as clinical evidence and supply conditions change.

Priority-setting should consider the severity of harm from interruption, the availability of therapeutic alternatives, the population served, the risk of disease transmission, workforce protection and the ability of facilities to use the product safely. Decision-makers should document exceptions and monitor whether rural areas, low-income populations, smaller facilities or marginalised groups are disproportionately affected. Equity is not achieved by distributing identical quantities everywhere; it is achieved by responding fairly to different levels of need while preventing avoidable disadvantage.

5.5 INFORMATION SYSTEMS, GOVERNANCE AND LEARNING

Information systems support resilience by connecting product, inventory, shipment, consumption and supplier data. In the absence of visibility, organisations may discover shortages only after patients are affected.

Early-warning systems should identify low stock, delayed deliveries, abnormal consumption, quality holds, expiring inventory and supplier notifications. They should also distinguish between a local reporting issue and a systemic shortage requiring cross-regional action. Data standards, routine data-quality checks and practical dashboards are necessary to convert information into timely decisions.

Governance determines whether available information produces action. Responsibilities should be clear across ministries, procurement agencies, regulators, manufacturers, distributors and health facilities. Emergency response plans should establish who can approve substitutions, release buffer stocks, authorise alternative suppliers, change delivery routes and communicate with clinicians and the public. After a disruption, organisations should conduct after-action reviews to identify bottlenecks, revise risk registers and strengthen contracts or systems. Learning is essential because the causes of the next disruption may differ from the last one.

6. DISCUSSION

The analysis shows that supply chain disruption in essential medical products is rarely caused by a single event. A shortage often results from interacting vulnerabilities: a sudden demand increase may coincide with limited supplier capacity, incomplete stock data, constrained freight and unclear allocation rules. Focusing on only one stage, such as warehousing or procurement, can therefore create a false sense of preparedness. A resilient medical supply chain requires coordinated design across the full product lifecycle and across institutions that may have

different incentives, data systems and responsibilities.

Efficiency remains important because health systems must use limited resources responsibly. However, efficiency measured only by low unit cost, low inventory or high asset utilisation can create fragility. Critical medical products may require additional safeguards, including strategic stocks, supplier diversification, reserved production capacity, regional distribution options and active quality monitoring. These safeguards should be proportionate to the product's clinical importance, likelihood of disruption, lead time and availability of safe alternatives. A one-size-fits-all stock policy is unlikely to protect the products that matter most during a crisis.

Digital technologies can strengthen visibility, but technology alone cannot solve governance failures. Dashboards, barcode systems, shipment tracking and predictive analytics are most useful when data are accurate, responsibilities are clear and decision-makers are empowered to act. Similarly, emergency procurement can accelerate access, but it must maintain quality assurance and prevent the introduction of falsified, substandard or unsuitable products. Resilience therefore combines speed with control, and flexibility with accountability.

The collective nature of medical product supply chains is also important. Manufacturers, wholesalers, carriers, regulators, donors, procurement agencies and health facilities each influence availability. Collaboration should include routine sharing of supply-risk information, common definitions of critical products, coordinated demand planning and agreed procedures for

shortages. Public communication is equally necessary when shortages affect treatment choices. Clear information can help clinicians plan substitutions, reduce inappropriate hoarding and protect public trust.

7. CONCLUSION

Supply chain disruptions in essential medical products threaten patient safety, service continuity and public confidence. The study finds that resilient availability depends on integrated planning across forecasting, sourcing, manufacturing, quality assurance, inventory, transport, data visibility, allocation and governance. The most important risks are demand volatility, supplier concentration, production and quality failures, logistics interruptions, poor data and inequitable allocation during scarcity.

The analysis confirms that health systems should move beyond reactive shortage management. They should identify high-risk products in advance, map supply dependencies, maintain proportionate buffer capacity, pre-qualify alternatives, strengthen early-warning systems, protect cold-chain and last-mile delivery, and establish transparent allocation rules. These measures should be embedded in routine operations so that emergency response can be rapid without sacrificing quality or fairness.

A resilient supply system is not one that never experiences disruption; it is one that can detect disruption early, protect essential care, adapt responsibly and learn from failure. By treating medical product supply chains as a core component of health-system preparedness, organisations can reduce avoidable shortages and improve equitable access to life-saving products.

8. REFERENCES

1. Christopher, M., & Peck, H. (2004). Building the resilient supply chain. *The International Journal of Logistics Management*, 15(2), 1-14.
2. Sheffi, Y., & Rice, J. B. Jr. (2005). A supply chain view of the resilient enterprise. *MIT Sloan Management Review*, 47(1), 41-48.
3. Tang, C. S. (2006). Perspectives in supply chain risk management. *International Journal of Production Economics*, 103(2), 451-488.
4. Juttner, U. (2005). Supply chain risk management: Understanding the business requirements from a practitioner perspective. *The International Journal of Logistics Management*, 16(1), 120-141.
5. Pettit, T. J., Fiksel, J., & Croxton, K. L. (2010). Ensuring supply chain resilience: Development of a conceptual framework. *Journal of Business Logistics*, 31(1), 1-21.
6. Yadav, P. (2015). Health product supply chains in developing countries: Diagnosis of the root causes of underperformance and an agenda for reform. *Health Systems & Reform*, 1(2), 142-154.

7. Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., Moller, H., Mouchi, A. M., Pango, L., & Robertson, J. (2017). Essential medicines for universal health coverage. *The Lancet*, 389(10067), 403-476.
8. U.S. Food and Drug Administration. (2019). Drug shortages: Root causes and potential solutions. U.S. Department of Health and Human Services.
9. World Health Organization. (2020). Maintaining essential health services: Operational guidance for the COVID-19 context. World Health Organization.
10. World Health Organization. (2020). Priority medical devices for the COVID-19 response and associated technical specifications. World Health Organization.
11. Organisation for Economic Co-operation and Development. (2020). The face mask global value chain in the COVID-19 outbreak: Evidence and policy lessons. OECD Publishing.
12. Organisation for Economic Co-operation and Development. (2020). Trade interdependencies in COVID-19 goods. OECD Publishing.
13. Ivanov, D. (2020). Predicting the impacts of epidemic outbreaks on global supply chains: A simulation-based analysis on the coronavirus outbreak case. *Transportation Research Part E: Logistics and Transportation Review*, 136, 101922.
14. Ivanov, D., & Dolgui, A. (2020). Viability of intertwined supply networks: Extending the supply chain resilience angles towards survivability. *International Journal of Production Economics*, 224, 107688.
15. Queiroz, M. M., Ivanov, D., Dolgui, A., & Wamba, S. F. (2020). Impacts of epidemic outbreaks on supply chains: Mapping a research agenda amid the COVID-19 pandemic through a structured literature review. *Annals of Operations Research*, 319, 1159-1196.
16. Govindan, K., Mina, H., & Alavi, B. (2020). A decision support system for demand management in healthcare supply chains considering the epidemic outbreaks: A case study of coronavirus disease 2019. *Transportation Research Part E: Logistics and Transportation Review*, 138, 101967.
17. Chowdhury, P., Paul, S. K., Kaisar, S., & Moktadir, M. A. (2021). COVID-19 pandemic related supply chain studies: A systematic review. *Transportation Research Part E: Logistics and Transportation Review*, 148, 102271.
18. Paul, S. K., & Chowdhury, P. (2020). A production recovery plan in manufacturing supply chains for a high-demand item during COVID-19. *International Journal of Physical Distribution & Logistics Management*, 51(2), 104-125.
19. van Hoek, R. (2020). Research opportunities for a more resilient post-COVID-19 supply chain - closing the gap between research findings and industry practice. *International Journal of Operations & Production Management*, 40(4), 341-355.
20. Kwon, I. W. G., & Suh, T. (2004). Factors affecting the level of trust and commitment in supply chain relationships. *Journal of Supply Chain Management*, 40(2), 4-14.
21. World Health Organization. (2019). WHO global benchmark tool for evaluation of national regulatory systems of medical products. World Health Organization.
22. World Health Organization. (2021). Comprehensive review of the global vaccine action plan. World Health Organization.
23. European Medicines Agency. (2023). Medicine shortages: Guidance and information for patients and health-care professionals. European Medicines Agency.
24. U.S. Food and Drug Administration. (2020). Notifying FDA of a permanent discontinuance or interruption in manufacturing of certain drug or biological products. U.S. Department of Health and Human Services.
25. Mackey, T. K., Vian, T., & Kohler, J. (2018). The sustainable development goals as a framework to combat health-sector corruption. *Bulletin of the World Health Organization*, 96(9), 634-643.
26. Keesara, S., Jonas, A., & Schulman, K. (2020). COVID-19 and health care's digital revolution. *New England Journal of Medicine*, 382(23), e82.
27. Natarajan, K., et al. (2020). Digital health: A pathway to resilient health systems. *The Lancet Digital Health*, 2(11), e595-e596.

-
28. World Bank. (2020). *Procurement in the COVID-19 context: Rapid response and emergency operations*. World Bank Group.
 29. United Nations Children's Fund. (2021). *UNICEF supply annual report 2020*. UNICEF Supply Division.
 30. United Nations Office for Project Services. (2021). *Procurement and supply chain management in health emergencies: Lessons for resilient systems*. UNOPS.